Free tool
Medicare drug spending
Last checked: Nov 19, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
4,424
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 100 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Eliquis Apixaban | D | $20.8B | +14% | 4,424,796 | $4,695 | $9.64 |
| Ozempic Semaglutide | D | $13.0B | +41% | 1,952,637 | $6,642 | $306.48 |
| Jardiance Empagliflozin | D | $11.4B | +29% | 2,543,331 | $4,496 | $18.94 |
| Mounjaro Tirzepatide | D | $6.34B | +168% | 894,581 | $7,084 | $511.63 |
| Xarelto Rivaroxaban | D | $6.23B | -1% | 1,321,019 | $4,718 | $17.68 |
| Keytruda Pembrolizumab · J9271 | B | $5.99B | +10% | 75,361 | $79,464 | $55.72 |
| Trulicity Dulaglutide | D | $5.45B | -26% | 788,716 | $6,915 | $467.75 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | D | $5.29B | +19% | 1,268,914 | $4,172 | $10.52 |
| Farxiga Dapagliflozin Propanediol | D | $5.29B | +22% | 1,269,216 | $4,168 | $18.31 |
| Humira(Cf) Pen Adalimumab | D | $4.33B | -2% | 63,768 | $67,882 | $3,531.42 |
| Revlimid Lenalidomide | D | $4.18B | +8% | 38,868 | $107,531 | $854.82 |
| Entresto Sacubitril/Valsartan | D | $4.02B | +17% | 795,291 | $5,055 | $11.04 |
| Januvia Sitagliptin Phosphate | D | $3.81B | -7% | 828,288 | $4,597 | $17.97 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | D | $3.46B | +10% | 92,246 | $37,466 | $131.33 |
| Xtandi Enzalutamide | D | $3.40B | +31% | 35,367 | $96,157 | $150.09 |
| Stelara* Ustekinumab | D | $3.38B | +13% | 24,754 | $136,463 | $26,534.27 |
| Vyndamax Tafamidis | D | $2.83B | +110% | 13,925 | $203,290 | $743.93 |
| Lenalidomide Lenalidomide | D | $2.64B | +57% | 30,354 | $87,002 | $655.88 |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj · J9144 | B | $2.53B | +22% | 26,517 | $95,426 | $49.11 |
| Prolia* Denosumab* · J0897 | B | $2.43B | +11% | 700,724 | $3,469 | $25.47 |
| Eylea Aflibercept · J0178 | B | $2.37B | -25% | 293,280 | $8,065 | $825.90 |
| Enbrel Sureclick Etanercept | D | $2.34B | +14% | 38,591 | $60,562 | $1,821.23 |
| Myrbetriq Mirabegron | D | $2.30B | -8% | 762,957 | $3,011 | $14.95 |
| Imbruvica Ibrutinib | D | $2.27B | -4% | 15,351 | $147,629 | $478.65 |
| Pomalyst Pomalidomide | D | $2.15B | +26% | 14,325 | $150,103 | $1,094.75 |
| Ofev Nintedanib Esylate | D | $2.09B | +14% | 23,929 | $87,191 | $216.45 |
| Jakafi Ruxolitinib Phosphate | D | $2.08B | +7% | 15,713 | $132,549 | $283.65 |
| Ibrance Palbociclib | D | $2.04B | +1% | 15,923 | $127,804 | $744.24 |
| Linzess Linaclotide | D | $1.98B | +9% | 632,063 | $3,136 | $17.69 |
| Ingrezza Valbenazine Tosylate | D | $1.96B | +15% | 32,171 | $60,819 | $272.77 |
| Opdivo Nivolumab · J9299 | B | $1.93B | +1% | 26,951 | $71,752 | $30.71 |
| Vabysmo Faricimab-Svoa · J2777 | B | $1.92B | +48% | 172,503 | $11,120 | $34.47 |
| Rybelsus Semaglutide | D | $1.89B | +13% | 309,993 | $6,097 | $30.59 |
| Invega Sustenna Paliperidone Palmitate | D | $1.88B | +3% | 72,112 | $26,045 | $2,352.66 |
| Dupixent Pen Dupilumab | D | $1.80B | +67% | 65,541 | $27,535 | $955.17 |
| Skyrizi Pen Risankizumab-Rzaa | D | $1.78B | +50% | 27,003 | $65,967 | $20,654.36 |
| Brukinsa Zanubrutinib | D | $1.72B | +115% | 18,031 | $95,633 | $121.31 |
| Repatha Sureclick Evolocumab | D | $1.71B | +57% | 382,461 | $4,470 | $269.54 |
| Calquence Acalabrutinib Maleate | D | $1.70B | +32% | 15,056 | $113,043 | $248.67 |
| Tagrisso Osimertinib Mesylate | D | $1.63B | +32% | 12,370 | $131,537 | $553.43 |
| Creon Lipase/Protease/Amylase | D | $1.49B | +2% | 185,261 | $8,061 | $8.76 |
| Membrane graft or membrane wrap, per square centimeter · Q4205 | B | $1.44B | +325% | 10,459 | $137,893 | $1,302.54 |
| Erleada Apalutamide | D | $1.39B | +31% | 13,253 | $104,603 | $233.33 |
| Rinvoq Upadacitinib | D | $1.39B | +42% | 29,062 | $47,673 | $218.53 |
| Breo Ellipta Fluticasone/Vilanterol | D | $1.36B | -1% | 596,052 | $2,283 | $6.50 |
| Restasis Cyclosporine | D | $1.29B | -14% | 472,657 | $2,729 | $10.20 |
| Opsumit Macitentan | D | $1.23B | +21% | 10,962 | $112,363 | $420.29 |
| Cabometyx Cabozantinib S-Malate | D | $1.22B | +10% | 9,182 | $132,512 | $826.87 |
| Complete ft, per square centimeter · Q4271 | B | $1.17B | +18769% | 5,091 | $229,484 | $1,636.66 |
| Xifaxan Rifaximin | D | $1.16B | +6% | 104,805 | $11,050 | $54.19 |
| Vraylar Cariprazine HCl | D | $1.14B | +21% | 117,573 | $9,662 | $48.73 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | D | $1.13B | +42% | 367,055 | $3,079 | $58.03 |
| Tradjenta Linagliptin | D | $1.13B | -13% | 274,523 | $4,107 | $16.56 |
| Austedo Deutetrabenazine | D | $1.07B | -5% | 18,418 | $57,927 | $103.14 |
| Verzenio Abemaciclib | D | $1.06B | +40% | 11,239 | $94,026 | $268.49 |
| Otezla Apremilast | D | $1.05B | +19% | 31,045 | $33,662 | $80.68 |
| Nubeqa Darolutamide | D | $998M | +73% | 11,577 | $86,211 | $110.35 |
| Tresiba Flextouch U-200 Insulin Degludec | D | $974M | -7% | 217,424 | $4,479 | $63.98 |
| Gemtesa Vibegron | D | $945M | +86% | 320,270 | $2,951 | $15.88 |
| Venclexta Venetoclax | D | $942M | +16% | 21,868 | $43,064 | $116.48 |
| Orencia* Abatacept* · J0129 | B | $930M | +3% | 33,154 | $28,062 | $42.48 |
| Uptravi* Selexipag | D | $909M | +20% | 4,320 | $210,364 | $354.19 |
| Spiriva Respimat Tiotropium Bromide | D | $877M | -5% | 327,575 | $2,678 | $119.52 |
| Lenvima Lenvatinib Mesylate | D | $876M | +12% | 8,450 | $103,626 | $491.21 |
| Rexulti Brexpiprazole | D | $861M | +37% | 94,695 | $9,096 | $49.56 |
| Imfinzi Durvalumab · J9173 | B | $843M | +14% | 14,791 | $56,999 | $79.68 |
| Tresiba Flextouch U-100 Insulin Degludec | D | $826M | +14% | 339,158 | $2,435 | $32.08 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | D | $819M | -6% | 291,195 | $2,813 | $7.58 |
| Cosentyx Sensoready (2 Pens) Secukinumab | D | $818M | -4% | 14,195 | $57,596 | $3,543.08 |
| Shingrix Varicella-Zoster Ge/As01b/PF | D | $776M | -36% | 2,933,003 | $264 | $196.56 |
| Kisqali Ribociclib Succinate | D | $775M | +109% | 8,782 | $88,305 | $296.84 |
| Arexvy Rsvpref3 Antigen/As01e/PF | D | $774M | -44% | 2,820,344 | $275 | $273.06 |
| Prolia Denosumab | D | $772M | +15% | 284,965 | $2,709 | $1,711.38 |
| Entyvio Vedolizumab · J3380 | B | $769M | +6% | 19,661 | $39,134 | $21.79 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 · J1569 | B | $765M | +3% | 26,102 | $29,310 | $44.60 |
| Epclusa Sofosbuvir/Velpatasvir | D | $758M | -14% | 12,242 | $61,921 | $848.72 |
| Atorvastatin Calcium Atorvastatin Calcium | D | $756M | -24% | 17,830,813 | $42 | $0.15 |
| Reblozyl Luspatercept-Aamt · J0896 | B | $755M | +67% | 6,466 | $116,808 | $39.53 |
| Restorigin, per square centimeter · Q4191 | B | $732M | +30150% | 5,256 | $139,204 | $1,481.65 |
| Tyvaso Dpi Treprostinil | D | $729M | +67% | 4,385 | $166,192 | $200.41 |
| Trikafta Elexacaftor/Tezacaftor/IVacaft | D | $725M | +7% | 2,732 | $265,267 | $308.31 |
| Vascepa Icosapent Ethyl | D | $724M | -5% | 301,070 | $2,405 | $2.87 |
| Oxervate Cenegermin-Bkbj | D | $715M | +45% | 4,781 | $149,456 | $2,011.76 |
| Janumet Sitagliptin Phos/Metformin HCl | D | $709M | -11% | 159,321 | $4,451 | $8.97 |
| Lantus Solostar Insulin Glargine,Hum.Rec.Anlog | D | $699M | -78% | 1,415,422 | $494 | $6.11 |
| Humira Pen Adalimumab | D | $697M | -16% | 11,719 | $59,511 | $3,351.33 |
| Comirnaty * Covid Vac (12up)(Raxt)/PF* · 91320 | B | $696M | +58% | 4,283,296 | $163 | $143.04 |
| Adempas Riociguat | D | $694M | +16% | 5,553 | $125,022 | $154.23 |
| Abiraterone Acetate Abiraterone Acetate | D | $693M | -21% | 55,274 | $12,536 | $22.11 |
| Dupixent Syringe Dupilumab | D | $687M | +8% | 22,833 | $30,093 | $967.95 |
| Brilinta Ticagrelor | D | $685M | -1% | 242,931 | $2,822 | $7.26 |
| Tecentriq Atezolizumab · J9022 | B | $678M | -10% | 10,191 | $66,497 | $83.43 |
| Promacta Eltrombopag Olamine | D | $672M | +21% | 6,666 | $100,867 | $408.06 |
| Ocrevus Ocrelizumab · J2350 | B | $669M | -4% | 11,764 | $56,845 | $57.58 |
| Eylea Hd Aflibercept · J0177 | B | $666M | n/a | 66,767 | $9,972 | $330.00 |
| Basaglar Kwikpen U-100 Insulin Glargine,Hum.Rec.Anlog | D | $665M | +3% | 422,745 | $1,572 | $20.79 |
| Nuplazid Pimavanserin Tartrate | D | $658M | +10% | 17,122 | $38,420 | $165.57 |
| Lumigan Bimatoprost | D | $647M | -7% | 336,870 | $1,921 | $96.72 |
| Abilify Maintena Aripiprazole | D | $644M | +1% | 29,911 | $21,538 | $2,722.42 |
| Padcev Enfortumab Vedotin-Ejfv · J9177 | B | $641M | +106% | 5,839 | $109,818 | $35.32 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.